Prognostic value of IL-27 polymorphisms and the susceptibility to epithelial ovarian cancer in a Chinese population

Immunogenetics

Volumn 66, Issue 2, 2014, Pages 85-92

  Zhang, Zhu ^a   Zhou, Bin ^a   Wu, Yuke ^a   Gao, Qianqian ^a   Zhang, Kui ^a   Song, Yaping ^a   Zhang, Lin ^a   Xi, Mingrong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Gynecologicmalignancy; Immunogenetics; Single nucleotide polymorphism; Survival analysis

Indexed keywords

INTERLEUKIN 27; PACLITAXEL; IL27 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADOLESCENT; ADULT; AGED; APPENDECTOMY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHINESE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HUMAN; HYSTERECTOMY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OMENTECTOMY; OVARIECTOMY; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; UNIVARIATE ANALYSIS; ALLELE; ASIAN; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MORTALITY; NEOPLASM; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PROGNOSIS; RISK FACTOR; SURVIVAL;

ADOLESCENT; ADULT; AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INTERLEUKINS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84897018171     PISSN: 00937711     EISSN: 14321211     Source Type: Journal    
DOI: 10.1007/s00251-013-0753-2     Document Type: Article

References (37)

1. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. Journal of clinical oncology 25(33):5165-5171. doi:10.1200/JCO.2007.11.5345 (Pubitemid 350237599)
2. Chae SC, Li CS, Kim KM, Yang JY, Zhang Q, Lee YC, Yang YS, Chung HT (2007) Identification of polymorphisms in human interleukin-27 and their association with asthma in a Korean population. Journal of human genetics 52(4):355-361. doi:10.1007/s10038-007-0123-8 (Pubitemid 46496297)
3. Chen Q, Ghilardi N, Wang H, Baker T, Xie MH, Gurney A, Grewal IS, de Sauvage FJ (2000) Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 407(6806):916-920. doi:10.1038/35038103
4. Chiyo M, Shimozato O, Yu L, Kawamura K, Iizasa T, Fujisawa T, Tagawa M (2005) Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. International journal of cancer Journal international du cancer 115(3):437-442. doi:10.1002/ijc.20848
5. Cocco C, Di Carlo E, Zupo S, Canale S, Zorzoli A, Ribatti D, Morandi F, Ognio E, Airoldi I (2012) Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo. Leukemia 26(6): 1365-1374. doi:10.1038/leu.2011.363
6. Devergne O, Hummel M, Koeppen H, Le Beau MM, Nathanson EC, Kieff E, Birkenbach M (1996) A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. Journal of virology 70(2):1143-1153 (Pubitemid 26029036)
7. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. The Journal of clinical investigation 102(7):1369-1376. doi:10.1172/JCI2629 (Pubitemid 28467565)
8. Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y, Mizuguchi J, Yoshimoto T (2004) Potent antitumor activity of interleukin-27. Cancer research 64(3):1152-1156 (Pubitemid 38176923)
9. Hu P, Hu HD, Chen M, Peng ML, Tang L, Tang KF, Matsui M, Belladonna ML, Yoshimoto T, Zhang DZ, Xiang R, Ren H (2009) Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Molecular immunology 46(8-9): 1654-1662. doi:10.1016/j.molimm.2009.02.025
10. Huang N, Liu L, Wang XZ, Liu D, Yin SY, Yang XD (2008) Association of interleukin (IL)-12 and IL-27 gene polymorphisms with chronic obstructive pulmonary disease in a Chinese population. DNA and cell biology 27(9):527-531. doi:10.1089/dna.2007.0715
11. Huang ZQ, Wang JL, Pan GG, Wei YS (2012) Association of single nucleotide polymorphisms in IL-12 and IL-27 genes with colorectal cancer risk. Clinical biochemistry 45(1-2):54-59. doi:10.1016/j.clinbiochem.2011.10.004
12. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331-1338. doi:10.1016/S0140-6736(09)61157-0
13. Li CS, Zhang Q, Lee KJ, Cho SW, Lee KM, Hahm KB, Choi SC, Yun KJ, Chung HT, Chae SC (2009) Interleukin-27 polymorphisms are associated with inflammatory bowel diseases in a Korean population. Journal of gastroenterology and hepatology 24(10):1692-1696. doi:10.1111/j.1440-1746.2009.05901.x
14. Li Y, Kang S, Qin JJ, Wang N, Zhou RM, Sun HY (2012) nm23 gene polymorphisms are associated with survival of patients with epithelial ovarian cancer but not with susceptibility to disease. Gynecologic oncology 126(3):455-459. doi:10.1016/j.ygyno.2012.06.004
15. Lucas S, Ghilardi N, Li J, de Sauvage FJ (2003) IL-27 regulates IL-12 responsiveness of naive CD4+ Tcells through Stat1-dependent and - independent mechanisms. Proc Natl Acad Sci U S A 100(25): 15047-15052. doi:10.1073/pnas. 2536517100 (Pubitemid 37518014)
16. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC Jr, Berchuck A (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer research 51(11):2979-2984
17. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding Wet al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66-71 (Pubitemid 24345325)
18. Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, Hara I, Nishigori C (2006) Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer research 66(12):6395-6404. doi:10.1158/0008-5472.CAN-05-4087
19. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, Hibbert L, Churakova T, Travis M, Vaisberg E, Blumenschein WM, Mattson JD, Wagner JL, To W, Zurawski S, McClanahan TK, Gorman DM, Bazan JF, de Waal MR, Rennick D, Kastelein RA (2002) IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 16(6):779-790 (Pubitemid 34786477)
20. Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, Phillips JH, McClanahan TK, de Waal MR, Kastelein RA (2004) WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 172(4):2225-2231 (Pubitemid 38182370)
21. Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, Hahn C, Shafer-Weaver K, Malyguine A, Kastelein R, Wigginton JM (2004) IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J Immunol 173(12):7170-7182 (Pubitemid 39628152)
22. Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, Kudo M, Iwakura Y, Takeda Y, Luster AD, Mizuguchi J, Yoshimoto T (2006) Antiangiogenic and antitumor activities of IL-27. J Immunol 176(12):7317-7324 (Pubitemid 43849032)
23. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA: a cancer journal for clinicians 63(1):11-30. doi:10.3322/caac.21166
24. Smith AJ, Humphries SE (2009) Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine & growth factor reviews 20(1):43-59. doi:10.1016/j.cytogfr.2008.11.006
25. Smith AJ, D'Aiuto F, Palmen J, Cooper JA, Samuel J, Thompson S, Sanders J, Donos N, Nibali L, Brull D, Woo P, Humphries SE (2008) Association of serum interleukin-6 concentration with a functional IL6-6331T>C polymorphism. Clinical chemistry 54(5):841-850. doi:10.1373/clinchem.2007.098608 (Pubitemid 351671601)
26. Sprecher CA, Grant FJ, Baumgartner JW, Presnell SR, Schrader SK, Yamagiwa T, Whitmore TE, O'Hara PJ, Foster DF (1998) Cloning and characterization of a novel class I cytokine receptor. Biochemical and biophysical research communications 246(1):82-90. doi:10.1006/bbrc.1998.8576 (Pubitemid 28413931)
27. Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, Yoshimura A, Yoshida H (2003) Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol 170(10):4886-4890 (Pubitemid 36554716)
28. Tao YP, Wang WL, Li SY, Zhang J, Shi QZ, Zhao F, Zhao BS (2012) Associations between polymorphisms in IL-12A, IL-12B, IL-12Rbeta1, IL-27 gene and serum levels of IL-12p40, IL-27p28 with esophageal cancer. Journal of cancer research and clinical oncology 138(11):1891-1900. doi:10.1007/s00432-012-1269-0
29. Terry CF, Loukaci V, Green FR (2000) Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. The Journal of biological chemistry 275(24):18138-18144. doi:10.1074/jbc.M000379200 (Pubitemid 30414764)
30. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B (2003) Survival and prognostic factors in patients with ovarian cancer. Obstetrics and gynecology 101(5 Pt 1):885-891 (Pubitemid 36561249)
31. Villarino A, Hibbert L, Lieberman L, Wilson E, Mak T, Yoshida H, Kastelein RA, Saris C, Hunter CA (2003) The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19(5):645-655 (Pubitemid 37490790)
32. Wang M, Zhu XY, Wang L, Lin Y (2013) The -607C/A polymorphisms in interleukin-18 gene promoter contributes to cancer risk: evidence from a meta-analysis of 22 case-control studies. PloS one 8(10): e76915. doi:10.1371/journal.pone.0076915
33. Wei YS, Lan Y, Luo B, Lu D, Nong HB (2009) Association of variants in the interleukin-27 and interleukin-12 gene with nasopharyngeal carcinoma. Molecular carcinogenesis 48(8):751-757. doi:10.1002/mc.20522
34. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789-792. doi:10.1038/378789a0 (Pubitemid 26004412)
35. Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, Oniki S, Oka M, Nishigori C, Mizuguchi J (2008) Antiproliferative activity of IL-27 on melanoma. J Immunol 180(10):6527-6535
36. Zhang Z, Zhou B, Zhang J, Chen Y, Lai T, Yan L, Liang A, Li Y, Wang Y, Zhang L, Xi MR (2010) Association of interleukin-23 receptor gene polymorphisms with risk of ovarian cancer. Cancer genetics and cytogenetics 196(2):146-152. doi:10.1016/j.cancergencyto.2009.09.006
37. Zhao B, Meng LQ, Huang HN, Pan Y, Xu QQ (2009) A novel functional polymorphism, 16974 A/C, in the interleukin-12-3′ untranslated region is associated with risk of glioma. DNA and cell biology 28(7):335-341. doi:10.1089/dna.2008.0845